[Illinois] Cancer Community Symposium 2012: A Sensitivity Scale for Targeting T Cells with Chimeric Antigen Receptors (CAR) and Bispecific T Cell Engagers (BiTE)
09 May 2012 | | Contributor(s):: Jennifer Stone
Using a patients immune system to target cancer and maintain long-term surveillance is an attractive goal. Although T cells can respond potently to tumors, immune tolerance mechanisms often result in deletion or inactivation of those T cells expressing specific T cell receptors (TCRs) against...
[Illinois] Cancer Community Symposium 2012: DriveRank: Discovering Patient-Specific Driver Mutations
09 May 2012 | | Contributor(s):: Jack Pu Hou
One of the pressing challenges in cancer genomics is to distinguish driver mutations (i.e. mutations involved in tumorigenesis) and passenger mutations (i.e. functionally neutral mutations). Current approaches to identifying driver mutations in cancer look for recurrent events in multiple...
[Illinois] Cancer Community Symposium 2012: Elevated Estrogen Signaling Drives Tumorigenesis in a Novel Animal Model for Ovarian Epithelial Cancer
09 May 2012 | | Contributor(s):: Mary Jo Laws
We generated a mouse model where aberrant estrogen receptor alpha (Esr1) signaling in the hypothalamo-pituitary-ovarian axis leads to ovarian tumorigenesis. In this model, termed Esr1d/d, the Esr1 gene is selectively deleted in the anterior pituitary. The Esr1d/d mice form palpable ovarian tumors...
Appreciating Nature's Antibiotics as Chemical Treasures
12 Jul 2011 | | Contributor(s):: Christopher T. Walsh
This lecture is part of the 28th Annual H.C. Brown Lectures in Organic Chemistry.
How to Engineer Human Microbiomes?
02 Mar 2017 | | Contributor(s):: Mohit Verma
We are developing tools based on nanotechnology, bioengineering, and analytical chemistry to understand causal relationships between microbiomes and their hosts, and to manipulate microbiomes for desirable outcomes, e.g. to shift patients from unhealthy to healthy states. One of these tools uses...
Illinois 2011 NanoBiophotonics Summer School Lecture 3: Introduction to Cellular Bioengineering
04 Dec 2011 | | Contributor(s):: Yingxiao Wang
Illinois BioNanotechnology Seminar Series Fall 2011: Deconvolving Stiffness in MEMS Pedestal Cell Mass Measurements
05 Dec 2011 | | Contributor(s):: Elise Corbin
The complex relationships between a cell's behavior and the physical properties of both itself and its environment have long been of interest. Specifically, the understanding the mechanisms through which a cell's physical properties influence cell growth, cell differentiation, cell cycle...
Illinois Nano EP Seminar Series Spring 2011: Interfacing Engineering, Biology, and Medicine at the Micro and Nano Scale
13 Dec 2011 | | Contributor(s):: Rashid Bashir
In this talk, we will present an overviewof our work in Silicon-Based BioMEMS and Bionanotechnology and discuss the state of the art and thefuture challenges and opportunities. We will review a range of projects in our group focused towardsdeveloping rapid detection of biological entities and...
KIST/PU The Professor’s Challenge: To commercialize or not, that is the question?
06 Dec 2011 | | Contributor(s):: J. Paul Robinson
Outline:Outline the Professors DilemmaShow what the normal criteria for research project direction isDiscuss the Corporate perspectiveDiscuss an example of failed innovationDemonstrate how time can impact an innovative ideaConclusions
KIST/PU Theragnosis – A New Paradigm of Personalized Medicine
06 Dec 2011 | | Contributor(s):: Ick Chan Kwon
Companion Diagnosis, based on pharmacogenomics, has been recognized as one of most important key representatives of personalized medicine. However, Companion Diagnosis does not provide any clues in developing new ways of therapeutics but it only provides a best choice of drugs based on given...
[Illinois] BioEngineering Seminar Series: Novel Receptor-Targeting Radiolabeled Peptides for Cancer Imaging
26 Nov 2012 | | Contributor(s):: Yubin Miao
Gonadotropin-releasing hormone (GnRH) and melanocortin-1 (MC1) receptors are attractive molecular targets for cancer imaging due to their over-expressions on cancer cells. GnRH and alpha-melanocyte stimulating hormone (α-MSH) peptides can bind the GnRH and MC1 receptors with nanomolar...
[Illinois] BioNanotechnology Seminar Series Spring 2013: Using Primary Cells for Bioengineering
14 May 2013 | | Contributor(s):: Mahendra S. Rao
[Illinois] Biophotonics 2011: Intro to Cellular Bioengineering
15 Jun 2012 | | Contributor(s):: Yingxiao "Peter" Wang
Biophotonics Summer School 2011The Biophotonics Summer School brings together from a wide variety of disciplines to teach students about the biophotonics field. In 2011, some of the topics covered included principles of biophotonics, technology and methods of investigation. The latest research...
[Illinois] CABPN Workshop
26 Nov 2012 | | Contributor(s):: Rashid Bashir, Matthew V. Schulmerich, Jianjun Cheng, Brian Cunningham, William Helferich, Manas Ranjan Gartia, Jozef L. Kokini, Lila Vodkin
CABPN is a National Science Foundation (NSF) Industry/University Cooperative Research Center. Its mission is to conduct industry-relevant fundamental research, enhance graduate education and research, and to facilitate technology transfer to industry.(Source: http://cabpn.illinois.edu/index.php)
[Illinois] Cancer Community Symposium 2012: An Integrated Approach to Cancer Research
09 May 2012 | | Contributor(s):: John F. McDonald
The field of cancer biology is rapidly moving from an era of specialization to an era of integration. In my presentation, I will provide examples of the integration of molecular biology with analytical chemistry, computer science/machine learning and material science/nanotechnology to develop...
[Illinois] Cancer Community Symposium 2012: Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB Signaling
09 May 2012 | | Contributor(s):: Elvira de Mejia
Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB SignalingLunasin is a promising chemopreventive agent. The objective was to study the effect of lunasin on human colon cancer...
[Illinois] Cancer Community Symposium 2012: Chemical Imaging for Histopathology: An Emerging Route for Molecular and Structural Analysis of Tissues
09 May 2012 | | Contributor(s):: Michael Walsh
Mid-Infrared (IR) spectroscopic imaging is an emerging approach to derive chemical images from tissues based on their inherent biochemistry. Histologic diagnosis is the gold standard for evaluating the presence and severity of most diseases. Current histopathological techniques use of panel of...
[Illinois] Cancer Community Symposium 2012: Closing Address and Awards
09 May 2012 | | Contributor(s):: Rohit Bhargava
Jaeyun Sung announces the awards from the poster sessions. Dr. Rohit Bhargava provides the audience with reflections on the conference and thoughts going forward.Cancer Community At Illinois Symposium 2012 April 5-6, 2012: Connecting patient care, research, and scientific advancementSymposium...
[Illinois] Cancer Community Symposium 2012: Imaging Estrogen Receptors and Estrogen-Receptor Function in Breast Cancer by Positron Emission Tomography (PET): Improved Selection of Patients for Benefit from Endocrine Therapies
09 May 2012 | | Contributor(s):: John A. Katzenellenbogen
The growth of many breast cancers is regulated by estrogens, and these cancers can be treated effectively with endocrine therapies (ET). Identifying patients who will benefit from ET, however, continues to be challenging. Measurement of estrogen receptor (ER) levels in tumor biopsy samples using...
[Illinois] Cancer Community Symposium 2012: Materials Science vs. Metastasis
09 May 2012 | | Contributor(s):: Daniel A. Heller
Metastasis, the spread of cancer cells from a primary tumor to seed secondary tumors in distant sites, is one of the greatest challenges in cancer treatment today. For many patients, by the time cancer is detected, metastasis has already occurred. Over 80% of patients diagnosed with lung cancer,...